Tumor-targeting RNAi oligonucleotide therapy have been proposed as a possible therapeutic intervention and, as a matter of fact, a clinical trial to inhibit STAT3 with oligonucleotides in combination with radiation therapy is currently in phase I for Relapsed/Refractory B-Cell NHL [59]; (ClinicalTrials.gov NCT04995536). This evidence concerns the gene STAT3 and B-cell non-Hodgkin lymphoma.